OBJECTIVES: To identify predictors of outcomes in patients with localized prostate cancer treated with iodine-125 brachytherapy in a longitudinal uncontrolled study. METHODS: Between 2000 and 2011, 560 histologically confirmed patients were treated with brachytherapy of whom 305 with ≥24-month follow-up and localized tumor were evaluated after exclusion of those locally advanced and under androgen ablation. RESULTS: Patients' mean age was 63.93 years (44-88), mean pretreatment prostate-specific antigen (PSA) was 6.34 ng/mL (0.67-33.09), overall median follow-up was 75.35 months (24-158.37), biochemical recurrence occurred in 17 patients (5.57 %), cancer-specific survival was 100 %, and overall survival was 98.03 %. At multivariate analyses, only PSA-nadir at 1 year and age were related to disease-free survival: To each unit of PSA-nadir, the risk increases 87.3 %-OR 1.87 (p < 0.001; 95 % CI 1.31-2.67), and risk was 4.7 times higher for those under 50 years (vs. >70)-OR 4.69 (p = 0.04; 95 % CI 1.39-18.47). Best cutoff for PSA-nadir at one year was 0.285 (AUC = 0.78; p < 0.001; 95 % CI 0.68-0.89). Kaplan-Meier analysis confirmed PSA-nadir (p < 0.001) as prognostic, while D'Amico's classification failed (p = 0.24). No grade 3 or 4 complication was reported, and only 31.4 % of patients had grade 2 urinary or rectal toxicity. PSA bounce ≥0.4 ng/mL occurred in 18.4 % with no impact on biochemical recurrence. CONCLUSIONS: Half (50.49 %) of patients in the scenario of localized prostate cancer treated with iodine-125 brachytherapy reach PSA-nadir at 1 year <0.285, recognized as a key independent prognostic factor.
OBJECTIVES: To identify predictors of outcomes in patients with localized prostate cancer treated with iodine-125 brachytherapy in a longitudinal uncontrolled study. METHODS: Between 2000 and 2011, 560 histologically confirmed patients were treated with brachytherapy of whom 305 with ≥24-month follow-up and localized tumor were evaluated after exclusion of those locally advanced and under androgen ablation. RESULTS:Patients' mean age was 63.93 years (44-88), mean pretreatment prostate-specific antigen (PSA) was 6.34 ng/mL (0.67-33.09), overall median follow-up was 75.35 months (24-158.37), biochemical recurrence occurred in 17 patients (5.57 %), cancer-specific survival was 100 %, and overall survival was 98.03 %. At multivariate analyses, only PSA-nadir at 1 year and age were related to disease-free survival: To each unit of PSA-nadir, the risk increases 87.3 %-OR 1.87 (p < 0.001; 95 % CI 1.31-2.67), and risk was 4.7 times higher for those under 50 years (vs. >70)-OR 4.69 (p = 0.04; 95 % CI 1.39-18.47). Best cutoff for PSA-nadir at one year was 0.285 (AUC = 0.78; p < 0.001; 95 % CI 0.68-0.89). Kaplan-Meier analysis confirmed PSA-nadir (p < 0.001) as prognostic, while D'Amico's classification failed (p = 0.24). No grade 3 or 4 complication was reported, and only 31.4 % of patients had grade 2 urinary or rectal toxicity. PSA bounce ≥0.4 ng/mL occurred in 18.4 % with no impact on biochemical recurrence. CONCLUSIONS: Half (50.49 %) of patients in the scenario of localized prostate cancer treated with iodine-125 brachytherapy reach PSA-nadir at 1 year <0.285, recognized as a key independent prognostic factor.
Authors: Mark J Rivard; Wayne M Butler; Phillip M Devlin; John K Hayes; Robert A Hearn; Eugene P Lief; Ali S Meigooni; Gregory S Merrick; Jeffrey F Williamson Journal: Brachytherapy Date: 2007 Jan-Mar Impact factor: 2.362
Authors: John E Sylvester; Peter D Grimm; Jason Wong; Robert W Galbreath; Gregory Merrick; John C Blasko Journal: Int J Radiat Oncol Biol Phys Date: 2010-09-23 Impact factor: 7.038
Authors: Al V Taira; Gregory S Merrick; Wayne M Butler; Robert W Galbreath; Jonathan Lief; Edward Adamovich; Kent E Wallner Journal: Int J Radiat Oncol Biol Phys Date: 2010-06-03 Impact factor: 7.038
Authors: David Bowes; Juanita M Crook; Kris Wallace; Andrew Evans; Ants Toi; Antonio Finelli; Michael A S Jewett; Neil Fleshner; Charles Catton Journal: Urology Date: 2012-06-13 Impact factor: 2.649
Authors: Edan Y Shapiro; Soroush Rais-Bahrami; Carol Morgenstern; Barbara Napolitano; Lee Richstone; Louis Potters Journal: J Urol Date: 2009-02-23 Impact factor: 7.450
Authors: Louis Potters; Carol Morgenstern; Emil Calugaru; Paul Fearn; Anup Jassal; Joseph Presser; Edward Mullen Journal: J Urol Date: 2008-05 Impact factor: 7.450
Authors: Gregory S Merrick; Kent E Wallner; Robert W Galbreath; Wayne M Butler; Sarah G Brammer; Zachariah A Allen; Jonathan H Lief; Edward Adamovich Journal: Am J Clin Oncol Date: 2008-12 Impact factor: 2.339
Authors: Al V Taira; Gregory S Merrick; Robert W Galbreath; Kent E Wallner; Wayne M Butler Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-19 Impact factor: 7.038
Authors: Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz Journal: Nat Rev Urol Date: 2017-06-30 Impact factor: 14.432
Authors: Marcos Os Coelho; Luciana Sb Dal Col; Diego M Capibaribe; Carla M Salgado; Thiago C Travassos; Vanderlei J Junior; Carlos R Monti; Leonardo O Reis Journal: Am J Clin Exp Urol Date: 2022-02-15